These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16485142)

  • 21. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
    Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
    Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer?
    Khodapasand E; Jafarzadeh N; Farrokhi F; Kamalidehghan B; Houshmand M
    Iran Biomed J; 2015; 19(2):69-75. PubMed ID: 25864810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
    Kang SY; Han JH; Lee KJ; Choi JH; Park JI; Kim HI; Lee HW; Jang JH; Park JS; Kim HC; Kang S; Oh YT; Chun M; Kim JH; Sheen SS; Lim HY
    Clin Cancer Res; 2007 Jul; 13(14):4146-53. PubMed ID: 17634542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
    Chang SC; Lin JK; Yang SH; Wang HS; Li AF; Chi CW
    Int J Cancer; 2006 Apr; 118(7):1721-7. PubMed ID: 16231316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Variation in the prognostic value of p53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma].
    Díez M; Pollán M; Ramos P; Villeta R; Ratia T; Hernández P; Lozano O; Noguerales F; Granell J
    Cir Esp; 2005 Apr; 77(4):213-20. PubMed ID: 16420920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors.
    Addeo R; Crisci S; D'Angelo V; Vincenzi B; Casale F; Pettinato G; Donofrio V; Boldrini R; Alaggio R; Collini P; Bertorelle R; Di Tullio MT; Caraglia M; Terenziani M; Lo Curto M; Indolfi P
    Oncol Rep; 2007 May; 17(5):1155-61. PubMed ID: 17390059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the EP300, TP53 and BAX genes in colorectal cancer: Correlations with clinicopathological parameters and survival.
    Kowalczyk AE; Krazinski BE; Godlewski J; Kiewisz J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Kiezun J; Sulik M; Kmiec Z
    Oncol Rep; 2017 Jul; 38(1):201-210. PubMed ID: 28586030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor deposit is a poor prognostic indicator for patients who have stage II and III colorectal cancer with fewer than 4 lymph node metastases but not for those with 4 or more.
    Nagayoshi K; Ueki T; Nishioka Y; Manabe T; Mizuuchi Y; Hirahashi M; Oda Y; Tanaka M
    Dis Colon Rectum; 2014 Apr; 57(4):467-74. PubMed ID: 24608303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
    Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
    Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection.
    Liang JT; Chang KJ; Chen JC; Lee CC; Cheng YM; Hsu HC; Chien CT; Wang SM
    Hepatogastroenterology; 1999; 46(26):883-90. PubMed ID: 10370632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma.
    Georgiou A; Gomatos IP; Ferekidis E; Syrigos K; Bistola V; Giotakis J; Adamopoulos G; Androulakis G
    Eur J Surg Oncol; 2001 Sep; 27(6):574-80. PubMed ID: 11520092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneous expression of neuroendocrine marker proteins in human undifferentiated carcinoma of the colon and rectum.
    Grabowski P; Schönfelder J; Ahnert-Hilger G; Foss HD; Stein H; Berger G; Zeitz M; Scherübl H
    Ann N Y Acad Sci; 2004 Apr; 1014():270-4. PubMed ID: 15153444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucinous differentiation in colorectal cancer--indicator of poor prognosis?
    Langner C; Harbaum L; Pollheimer MJ; Kornprat P; Lindtner RA; Schlemmer A; Vieth M; Rehak P
    Histopathology; 2012 Jun; 60(7):1060-72. PubMed ID: 22348346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis.
    Boltze C
    Pathol Res Pract; 2005; 200(11-12):783-90. PubMed ID: 15792121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer.
    Betge J; Kornprat P; Pollheimer MJ; Lindtner RA; Schlemmer A; Rehak P; Vieth M; Langner C
    Ann Surg Oncol; 2012 Nov; 19(12):3706-12. PubMed ID: 22669453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
    Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
    Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.